SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Bayer

Status: Completed

Conditions: Chronic Bronchitis

Treatments: Drug: Moxifloxacin (Avelox, BAY12-8039)

Study type: Observational

Funder types: Industry

Identifiers

NCT00879008

AX0710DE (Other Identifier)

12629

Details and patient eligibility

About

In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.

Full description

The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.

Enrollment: 345 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute exacerbation of chronic bronchitis from Anthonisen type I or II
• FEV1 of < 50 %
• Patient must be ensured in the statutory health insurance
• Further contraindications of the prescribed pharmaceutical products must be considered

Exclusion criteria

• Patients who change from one cohort to the other

Trial design

345 participants in 1 patient group

Group 1

Treatment:

Drug: Moxifloxacin (Avelox, BAY12-8039)